It's always valuable to look at the underlying data when considering a ticker like GILD. Gilead Sciences, Inc. (GILD) is a significant player in the biopharmaceutical space, known for its work in antivirals, oncology, and inflammatory diseases.1
Here's a quick look at some key Fintel data points:
- Institutional Ownership: GILD has a substantial institutional presence, with 3,322 institutional owners holding a total of 1,311,983,058 shares long in the most recent quarter.2 Major holders include Vanguard Group Inc, BlackRock, Inc., and Fmr Llc.2 However, it's worth noting some recent shifts. For instance, a 13G/A filing from May 2025 indicated Capital World Investors decreased their GILD holdings by over 35%, and BlackRock, Inc. reduced theirs by over 17% in April 2025.3 This suggests some large institutional investors have been paring down their positions.
- Short Interest: The short interest in GILD stands at 22,539,960 shares, which represents 1.82% of the float.4 The off-exchange short volume ratio was 41.39%, indicating a notable portion of shorting activity occurring outside traditional exchanges.4 While not excessively high, this level of short interest can reflect some bearish sentiment in the market.
- Recent Performance & News: As of early August 2025, the share price was $110.28, experiencing a slight weekly decrease.1 Earlier in April 2025, Gilead had lowered its full-year profit guidance following a dip in Q1 sales.5 This could be a contributing factor to institutional adjustments and market sentiment.
Overall, while GILD maintains strong institutional backing, recent reductions by some major funds and a relatively stable short interest suggest a mixed sentiment that warrants deeper investigation into the company's fundamentals and pipeline developments.
